Silence Therapeutics PLC
NASDAQ:SLN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Silence Therapeutics PLC
Operating Income
Silence Therapeutics PLC
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Silence Therapeutics PLC
OTC:SLNCF
|
Operating Income
-£22.7m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Operating Income
-£45.4m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Operating Income
-$179m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Operating Income
£83m
|
CAGR 3-Years
10%
|
CAGR 5-Years
15%
|
CAGR 10-Years
8%
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Operating Income
-£32.4m
|
CAGR 3-Years
14%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
-9%
|
|
|
Niox Group PLC
LSE:NIOX
|
Operating Income
£10.7m
|
CAGR 3-Years
81%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Silence Therapeutics PLC
Glance View
Silence Therapeutics Plc engages in the discovery, delivery and development of ribonucleic acid (RNA) therapeutics. The firm is focused on discovering and developing molecules combining short interfering ribonucleic acid (siRNA), to inhibit the expression of target genes in the pathology of diseases with unmet medical need. Its siRNA molecules are designed to harness the body’s natural mechanism of RNA interference (RNAi), by specifically binding to and degrading messenger RNA, or mRNA, molecules that encode specific targeted disease-associated proteins in a cell. The Company’s mRNAi GOLD (GalNAc Oligonucleotide Discovery) platform is a platform of precision-engineered medicines designed to target for specific disease-associated genes in the liver. The Company’s clinical development programs include SLN360, for the prevalent unmet need in reducing cardiovascular risk in people born with Lipoprotein(a), or Lp(a), levels and SLN124, for rare iron loading anemia conditions, including thalassemia and myelodysplastic syndrome (MDS).
See Also
What is Silence Therapeutics PLC's Operating Income?
Operating Income
-22.7m
GBP
Based on the financial report for Dec 31, 2019, Silence Therapeutics PLC's Operating Income amounts to -22.7m GBP.
What is Silence Therapeutics PLC's Operating Income growth rate?
Operating Income CAGR 3Y
-24%
Over the last year, the Operating Income growth was -11%. The average annual Operating Income growth rates for Silence Therapeutics PLC have been -24% over the past three years .
